公開日期 | 題名 | 作者 | 關聯 | scopus | WOS | 全文 |
2008 | A mammalian cell-based reverse two-hybrid system for functional analysis of 3C viral protease of human enterovirus 71 | Lee, JC; Shih, SR; Chang, TY; Tseng, HY; Shih, YF; Yen, KJ; Chen, WC; Shie, JJ; Fang, JM; Liang, PH ; Chao, YS; Hsu, JT | Anal Biochemistry 375, 115-123 | | | |
2018 | Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma | Chen, YL; Hu, CM; Hsu, JT; Chang, CC; Huang, TY; Chiang, PH; Chen, WY; Chang, YT; Chang, MC; Tien, YW; Lee, EY; Jeng, YM; Lee, WH | American journal of cancer research 8(12), 2548-2563 | | | |
2004 | Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate | Kuo, CJ; Chi, YH; Hsu, JT; Liang, PH | Biochem Biophys Res Commun 318, 862-867 | | | |
2008 | Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents | Kuo, CJ; Shie, JJ; Fang, JM; Yen, GR; Hsu, JT; Liu, HG; Tseng, SN; Chang, SC; Lee, CY; Shih, SR; Liang, PH | BIOORGANIC & MEDICINAL CHEMISTRY 16, 7388-7398 | | | |
2004 | Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV | Hsu, JT; Kuo, CJ; Hsieh, HP; Wang, YC; Huang, KK; Lin, CP; Huang, PF; Chen, X; Liang, PH | FEBS Lett 574, 116-120 | | | |
2005 | Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3′-digallate (TF3) | Chen, CN; Lin, CP; Huang, KK; Chen, WC; Hsieh, HP; Liang, PH ; Hsu, JT | Evid Based Complement Alternat Med 2(2), 209-215 | | | |
2004 | Purification and characterization of human prolyl dipeptidase DPP8 in Sf9 insect cells | Chen, YS; Chien, CH; Goparaju, CM; Hsu, JT; Liang, PH ; Chen, X | Protein Expr Purif 35, 142-146 | | | |
2013 | T-cell immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by the recognition of airway cell death. | Kim, HY; Chang, YJ; Chuang, YT; Lee, HH; Kasahara, DI; Martin, T; Hsu, JT; Savage, PB; Shore, SA; Freeman, GJ; Dekruyff, RH; Umetsu, DT | The Journal of allergy and clinical immunology 132(2), 414-425.e6 | | | |